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Abstract. Background: Neutropenia and its complications
represent one of the principal dose-limiting toxicity issues in
chemotherapeutic regimens for soft tissue sarcoma.
Prophylactic granulocyte colony-stimulating factor (G-CSF)
reduces the risk of febrile neutropenia (FN). The correct
timing of G-CSF administration should be considered in order
to optimize the prophylactic treatment. Patients and Methods:
Patients (≥18 years old) affected by soft tissue sarcoma and
treated with epirubicin and ifosfamide, underwent prophylactic
treatment with G-CSF (lenograstim at 263 μg) from day 5 to
day 9. The proportion of patients experiencing FN and G4
neutropenia was considered. Results: A total of 36 patients
receiving three cycles of chemotherapy with epirubicin plus
ifosfamide were treated. None developed FN; G4 neutropenia
was reported in 17% of patients. No treatment delay or dose
reduction was required, no antibiotic therapy was
administered and no hospitalization occurred. Conclusion:
Five-day lenograstim treatment is efficient as prophylaxis of
FN for soft tissue sarcoma chemotherapy regimens and allows
maintenance of chemotherapy dose intensity.
Soft tissue sarcomas (STS) represent fewer than 1% of all
malignant tumors and originate from mesenchymal cells in all
parts of the body (1). The subcutaneous soft tissue of the limbs
is the most frequent site where it occurs (2, 3). Prognostic
factors, such as size, grading and location are considered before
therapeutic approaches are initiated (4). Combined modality
treatment, including surgery, radiotherapy and chemotherapy,
leads to local control in a high proportion of patients (5) and
reduces the occurrence of distant metastases (6-9).
The potential benefits of more aggressive combinations
are burdened by increased toxicities, mainly in the form of
dose-limiting myelosuppression (10-12). The most frequently
used chemotherapy schedules are anthracycline and
ifosfamide-based regimens, with a 58% febrile neutropenia
risk without use of prophylaxis with granulocyte colony
stimulating factor (G-CSF) (13).
Prophylactic administration of the G-CSF lenograstim, after
doxorubicin, ifosfamide and dacarbazine in patients with STS,
has been shown to improve hematological tolerance to
chemotherapy, leading to a significant reduction in the
duration of neutropenia, reduction of neutrophil recovery time,
and a reduction of febrile neutropenia incidence (13, 14).
The optimal timing and dose for successful G-CSF
prophylactic treatments are still being debated. According to
international guidelines, in settings characterized by an
elevated risk of neutropenia (20% or more), prophylaxis with
G-CSF at 5 μg/kg/day administered subcutaneously (s.c.)
should last between 24-72 hours after chemotherapy until a
sufficient/stable post-nadir absolute neutrophil count (ANC)
recovery is reached (15, 16). Alternatively, a single s.c.
administration of pegfilgrastim at a total dose of 6 mg is
considered equally effective and comparable to 11 injections
of daily G-CSF (17-19).
Nonetheless, in clinical practice, studies regarding
alternative G-CSF scheduling in moderate and high-intensity
chemotherapy regimens suggest that reducing the number of
G-CSF administrations is feasible without altering the
outcome (20, 21). A shorter G-CSF schedule seems to reduce
the incidence and the severity of short-term side-effects and
is more cost-effective (22-24). Furthermore, a large survey
by Falandry et al. regarding the prescription of G-CSF in
clinical practice was published recently and confirms
suboptimal compliance with international guidelines (25). In
particular, this observational study highlights that the
duration of daily G-CSF treatments is significantly shorter
than those reported in the guidelines: the mean G-CSF
administration was 5.5 days, only in 9.3% of the patients did
it exceed 7 days, and in only 6% of the patients did it exceed
10 days.
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According to prior studies in patients with STS receiving
anthracycline- and ifosfamide-based chemotherapy with G-
CSF, the neutrophil nadir is expected to occur by day 8
following the initiation of chemotherapy (13). The aim of
this study was to evaluate the incidence of febrile
neutropenia and grade 4 neutropenia in patients with STS
receiving lenograstim prophylaxis from days 5 to 9 after
starting chemotherapy.
Patients and Methods
Inclusion criteria for patients in this study were: ≥18 years old, a
diagnosis of STS, and treatment with epirubicin and ifosfamide.
Chemotherapy was admitted with adjuvant purpose, as well as in a
locally advanced or metastatic setting.
Epirubicin was administered as a bolus from day 1 to day 3 q21,
at a dose of 35 mg/m2/day; Ifosfamide was administered from day
1 to day 3 q21, at a dose of 3,000 mg/m2/day in a 2-hour infusion;
uroprotection with Mesna, hydration with an electrolyte and glucose
solution, and antiemetics were also administered.
Lenograstim was administered subcutaneously at a dose of 263 μg
from days 5 to 9 (five vials). Blood cell counts were performed on
days 8, 15 and 22 (Figure 1). Patients were observed for three cycles.
If a cycle was delayed for seven or more days due to
myelosuppression caused by the previous cycle treatment, doses of
chemotherapy agents were reduced by 25%.
In cases of febrile neutropenia, the patient was hospitalized and
empirical antibiotic therapy was initiated. Blood cultures were
carried out for specific antibiotic therapy. Monotherapy with an
antipseudomonal beta-lactam, such as the extended spectrum
cephalosporins or a carbapenem was used for uncomplicated
episodes. Combination regimens with a beta-lactam and either an
aminoglycoside or a fluoroquinolone were considered in the
treatment of complicated infections. Normal cardiac (left ventricular
ejection fraction) and renal function, neutrophil count ≥1,500×109/l,
hemoglobin ≥9 g/dl and platelets count ≥100,000 were required
before the first cycle. Patients who received prior chemotherapy,
patients with tumor infiltration of bone marrow (determined by
biopsy), and patients who were pregnant or breastfeeding were
excluded. All patients signed a written informed consent.
The primary endpoint was to identify the proportion of patients
experiencing febrile neutropenia, defined as the proportion of patients
experiencing ANC <1,000/mm3 and a single temperature of >38.3˚C
or a sustained temperature of ≥38˚C for more than one hour. The
secondary endpoints were to assess grade 4 neutropenia, defined as
the percentage of patients with ANC <500/mm3, the proportion of
patients experiencing dose reduction or treatment delays, and the
proportion of patients needing antibiotics or hospitalization.
Toxicity was graded using the Common Terminology Criteria for
Adverse Events (CTCAE) v.4.03 (26). All adverse events, attributed
to G-CSF that occurred during the study, as observed by the
investigator or reported by the patient, were recorded.
Descriptive statistics refer to all included patients. For continuous
variables, the mean, minimum and maximum values were
calculated. For each discrete variable, the number of cases in each
category was recorded.
Results
Between November 2009 and August 2010, 36 patients
affected by STS were treated in the Medical Oncology
Department of Palermo University, Italy. Patients’
characteristics are reported in Table I.
The median age was 53 (range 19-72) years. Most patients
(44%) were treated in an adjuvant setting. All patients
received three cycles of epirubicin (35 mg/m2 day 1-3 q21)
and ifosfamide (3,000 mg/m2 day 1-3 q21), for a total of 108
cycles. All cycles were evaluable for the study. Only four
patients received concomitant radiotherapy.
All patients received G-CSF prophylaxis with lenograstim
at 263 μg from days 5 to 9, according to the protocol
schedule (Figure 1).
Median neutrophil values for each cycle are reported in
Figure 2, according to the chemotherapy cycle. No febrile
neutropenia was reported. The incidence of grade 4
neutropenia was higher in the first cycle (14%) compared to
the second one (3%) and the third one (no patient) (Table II).
Considering the entire treatment period, grade 4 neutropenia
was reported in 17% of the patients. Most of the episodes of
neutropenia (58%) occurred on day 8, 29% on day 15 and
only two (13%) on day 22. In both the patients who
experienced neutropenia on day 22 (the day of the planned
subsequent cycle), the event was grade 3 and the total white
blood counts were within normal ranges.
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Figure 1. Treatment schedule. CBC: Complete blood count; CHT: chemotherapy; G-CSF: granulocyte colony-stimulating factor.
Twelve patients experienced at least one episode of
neutropenia; about one third had co-morbidities (Table I).
Overall, five patients developed two episodes of grade 4
neutropenia in two different cycles; in four, the first event
was grade 4 and the second was grade 3; in two, both events
were grade 3.
No treatment delay or dose reduction was required. No
dose modifications to growth factor prophylaxis were
required because of adverse events. No antibiotic therapy
was administered and no hospitalization occurred.
Neutrophil counts increased up to 10,000×109/l after
chemotherapy occurred in 6% of the cycles; only after two
cycles was ANC ≥20,000×109/l. The incidence of grade 3
anemia was 20%; no grade 4 anemia was reported; grade 3
thrombocytopenia was reported in 10% of the cycles. All
patients who experienced hematological toxicity recovered
with no after-effects.
No other grade 3-4 toxicities, except grade 3 vomiting (1
patient) and grade 3 nausea (3 patients), were reported.
Discussion
The prognosis for STS has improved over the past few years
thanks to better local control (6, 7). Controversies regarding
chemotherapy are still open even if adjuvant treatment seems
to increase both disease-free survival (DFS) and overall
survival (OS) (8, 9, 27). The potential benefits of more
aggressive chemotherapy regimens have been limited by
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Table I. Patients’ characteristics.
Variable (N=36)
Median age, years (range) 53 (19-72)
Gender n (%)
male/female 17 (48)/19 (52)
PS n (%)
0 30 (83)
1 6 (17)
≥2 0
Co-morbidities n (%)
Diabetes 1 (3)
Chronic renal failure 1 (3)
Hypercholesterolemia 1 (3)
Hypertension 7 (19)
Treatment setting n (%)
Neoadjuvant 4 (11)
Adjuvant 16 (44)
Locally advanced disease 6 (17)
Metastatic disease 10 (28)
Chemotherapy cycles completed n (%)
Yes 108 (100)
No 0
Concomitant radiotherapy n (%)
Yes 4 (11)
No 34 (89)
Figure 2. Neutrophil counts during cycle 1 (a), cycle 2 (b), cycle 3 (c) at
days 8, 15 and 22 for every patient; horizontal bars represent the
median value, boxes represent the 25th and 75th percentiles, whiskers
represent the range.
increased toxicity, in particular myelosuppression.
Neutropenia is a major cause of morbidity and mortality in
patients receiving chemotherapy, leading to a decrease in the
dose of cytotoxic agents, delaying the intervals between
cycles, and limiting the dose intensity of the treatment.
According to the EORTC guidelines, the risk of febrile
neutropenia for regimens used to treat STS, which include
anthracycline and ifosfamide, is over 50% without G-CSF
(16). Febrile neutropenia prophylaxis is therefore mandatory,
but the exact timing of G-CSF administration has not yet
been fully-established.
In this study, five vials of lenograstim were found to be
effective for preventing the risk of febrile neutropenia and
grade 4 neutropenia in regimens characterized by an elevated
risk. No episodes of febrile neutropenia were recorded and the
incidence of grade 4 neutropenia was lower than expected for
STS regimens (9, 13). These outcomes are particularly relevant
because they were obtained in a homogeneous population from
a single institution exposed to the same chemotherapy
schedule. The choice of lenograstim schedule (from days 5 to
9) respected both the ESMO and NCCN recommendations,
which state that the administration of daily G-CSF should start
24-72 hours after chemotherapy (15), and the onset of
neutrophil nadir. According to literature results, neutrophil
nadir is expected to occur on day 8 after the initiation of
anthracyline/ifosfamide-based treatment for STS (13).
The proposed schedule allowed the median neutrophil values
to remain within normal ranges for all the days considered
(days 8, 15, and 22) for every cycle (Figure 2). According to
previous studies, grade 4 neutropenia was more frequent in the
first chemotherapy cycle compared to the second or third cycles
(Table II and Figure 2) (27). The increase of neutrophils up to
normal limits was a rare event (6%) and the median values
were lower than those reported in literature (25).
Recent publications have pointed out a suboptimal
adherence to international guidelines for prophylaxis of
febrile neutropenia (14, 28). This could be related to the fact
that guidelines are often based on studies designed to assess
the efficacy of G-CSF versus placebo without evaluating the
proper timing and duration of G-CSF prophylaxis (28, 29).
Timing of G-CSF administration also considering the
neutrophil nadir could be useful for an optimization of
prophylaxis and could help physicians to administer the
lowest, fully effective, G-CSF dose, avoiding the possible
overlap with chemotherapy (30, 31).
The limits of this study are a possible selection bias due to
the sample size and the heterogeneity of the enrolled
population (adjuvant, neoadjuvant, palliative setting).
Moreover the lack of a randomized arm does not allow us to
confirm the superiority of this schedule over others.
However, in comparison to literature data, the use of five
vials of lenograstim at a dose of 263 μg seems effective in
preventing febrile neutropenia in patients with STS receiving
epirubicin and ifosfamide. This schedule of daily G-CSF
administration could be cost-effective and well-tolerated by
patients in terms of side-effects, efficacy, and compliance.
Further randomized trials are warranted to estabilish the gold
standard in the prophylaxis of chemotherapy-induced
neutropenia in patients with STS.
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